Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20343820 | 0.80 | MAPK14 (0.33) | HRH3MAPK14MAPK13SMN1; SMN2PBRM1 | |
| SCHEMBL1695290 | 0.78 | CYP3A4 (0.45) | APPMAPK14MAPK13 | |
| SCHEMBL254009 | 0.72 | GAA (0.44) | LMNAAPPHRH3MAPK14SMN1; SMN2 | |
| SCHEMBL16686865 | 0.72 | PIM1 (0.38) | KDM4EHRH3SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL12510331 | 0.72 | CCNC (0.45) | KDM4EMAPK14SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL12510429 | 0.72 | SCN5A (0.42) | KDM4EMAPK14MAPK13 | |
| SCHEMBL15028546 | 0.69 | BRD4 (0.33) | HRH3MAPK14SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL22479534 | 0.69 | ALDH1A1 (0.41) | HRH3MAPK14SMN1; SMN2PBRM1L3MBTL1 | |
| SCHEMBL12510431 | 0.69 | SCN5A (0.46) | KDM4ELMNAAPPHRH3SMN1; SMN2 | |
| SCHEMBL17616515 | 0.69 | SCN5A (0.47) | KDM4ELMNAHRH3MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557797-B2 | Triazolopyridine derivatives and their therapeutic use | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-10-15 | — | — | US | disclosed |
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CNKSR1, MOK, MAPK1 | KDM4E 3026/4885LMNA 2761/4885APP 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.